The pd-l1 and pik3ca testing market size has grown rapidly in recent years. It will grow from $1.67 billion in 2025 to $1.93 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to development of pd-l1 and pik3ca assays, adoption in clinical trials, growing cancer prevalence, advancements in molecular diagnostics, awareness of personalized therapy.
The pd-l1 and pik3ca testing market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to integration of ai in biomarker detection, growth of liquid biopsy applications, expansion in precision oncology, partnerships between diagnostics and pharma companies, regulatory approvals for next-gen assays. Major trends in the forecast period include targeted cancer biomarker testing, ai-based mutation analysis, liquid biopsy adoption, integration with drug development, high-throughput genomic screening.
The growing prevalence of cancer is expected to drive the expansion of the PD-L1 and PIK3CA testing market. Cancer, which is characterized by the uncontrolled growth and spread of abnormal cells, has become more common due to factors such as lifestyle-related risks and an aging population. These factors contribute to higher diagnosis rates and an increased demand for early detection and effective treatment solutions. PD-L1 and PIK3CA testing help manage cancer by providing accurate diagnoses and guiding targeted therapies, which allow treatments to be personalized to individual patients and improve clinical outcomes. For example, in September 2024, the American Cancer Society projected a significant increase in global cancer cases among men, estimating an 84% rise by 2029, from 10.3 million in 2022 to 19 million. This surge in cancer cases is driving the growth of the PD-L1 and PIK3CA testing market.
Key players in the PD-L1 and PIK3CA testing market are focusing on technological advancements, particularly the integration of companion diagnostics, to improve therapeutic targeting and enhance treatment efficacy in oncology. Companion diagnostic integration involves advanced testing systems designed alongside targeted medicines to identify patient groups most likely to benefit from specific treatments based on biomarker profiles. For instance, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, introduced Itovebi (inavolisib) in combination with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The FDA approved this regimen based on the Phase III INAVO120 study, which showed more than double the progression-free survival compared to palbociclib and fulvestrant alone. This marks Roche’s first targeted therapy for HR-positive disease and incorporates a companion diagnostic to identify eligible patients, representing a major step forward in precision medicine for a patient population with limited treatment options.
In September 2025, Labcorp, a U.S.-based provider of comprehensive clinical laboratory services and drug development solutions, purchased select oncology and oncology-related clinical testing assets from BioReference Health for up to $225 million. Through this acquisition, Labcorp seeks to broaden its oncology diagnostics portfolio and enhance nationwide access to high-value cancer testing services by incorporating BioReference’s specialized oncology capabilities and client accounts. BioReference Health is a U.S.-based provider of oncology-focused laboratory testing services, delivering advanced cancer diagnostics, clinical testing solutions, and regional clinical laboratory operations.
Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.
North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pd-l1 and pik3ca testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pd-l1 and pik3ca testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the pd-l1 and pik3ca testing market by increasing costs for imported sequencing kits, reagents, and diagnostic instruments. Hospitals, laboratories, and pharmaceutical companies in Asia-Pacific and Europe are most affected. Segments such as immunohistochemistry and next-generation sequencing kits face higher import costs. Positive impacts include promoting local manufacturing of reagents and kits, fostering innovation, and reducing dependency on international suppliers.
The pd-l1 and pik3ca testing market research report is one of a series of new reports that provides pd-l1 and pik3ca testing market statistics, including pd-l1 and pik3ca testing industry global market size, regional shares, competitors with a pd-l1 and pik3ca testing market share, detailed pd-l1 and pik3ca testing market segments, market trends and opportunities, and any further data you may need to thrive in the pd-l1 and pik3ca testing industry. This pd-l1 and pik3ca testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
PD-L1 and PIK3CA testing are molecular diagnostic methods used to identify specific biomarkers that support targeted cancer treatment decisions. PD-L1 testing measures the expression of the programmed death ligand 1 protein on tumor cells to evaluate the likelihood of response to immunotherapies. PIK3CA testing identifies mutations in the phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha gene, which helps determine eligibility for therapies directed at the PI3K pathway.
The primary test types of PD-L1 and PIK3CA testing include immunohistochemistry, next generation sequencing, polymerase chain reaction, and others. Immunohistochemistry is a laboratory method that applies antibodies to detect specific proteins in tissue samples, making it possible to visualize their location and concentration under a microscope. The sample types used are tissue samples and liquid biopsy samples. The distribution channels include direct sales, distributors and resellers, and online sales platforms. The applications involve cancer diagnosis, drug development, research, and other uses, and they serve multiple end users such as hospitals and clinics, laboratories, and pharmaceutical companies.
The PD-L1 and PIK3CA testing market includes revenues earned by entities through the biomarker testing, molecular diagnostics, genetic mutation detection, generation sequencing services, companion diagnostic testing, pathology interpretation, and clinical trial testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The pd-l1 and pik3ca testing market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to integration of ai in biomarker detection, growth of liquid biopsy applications, expansion in precision oncology, partnerships between diagnostics and pharma companies, regulatory approvals for next-gen assays. Major trends in the forecast period include targeted cancer biomarker testing, ai-based mutation analysis, liquid biopsy adoption, integration with drug development, high-throughput genomic screening.
The growing prevalence of cancer is expected to drive the expansion of the PD-L1 and PIK3CA testing market. Cancer, which is characterized by the uncontrolled growth and spread of abnormal cells, has become more common due to factors such as lifestyle-related risks and an aging population. These factors contribute to higher diagnosis rates and an increased demand for early detection and effective treatment solutions. PD-L1 and PIK3CA testing help manage cancer by providing accurate diagnoses and guiding targeted therapies, which allow treatments to be personalized to individual patients and improve clinical outcomes. For example, in September 2024, the American Cancer Society projected a significant increase in global cancer cases among men, estimating an 84% rise by 2029, from 10.3 million in 2022 to 19 million. This surge in cancer cases is driving the growth of the PD-L1 and PIK3CA testing market.
Key players in the PD-L1 and PIK3CA testing market are focusing on technological advancements, particularly the integration of companion diagnostics, to improve therapeutic targeting and enhance treatment efficacy in oncology. Companion diagnostic integration involves advanced testing systems designed alongside targeted medicines to identify patient groups most likely to benefit from specific treatments based on biomarker profiles. For instance, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, introduced Itovebi (inavolisib) in combination with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The FDA approved this regimen based on the Phase III INAVO120 study, which showed more than double the progression-free survival compared to palbociclib and fulvestrant alone. This marks Roche’s first targeted therapy for HR-positive disease and incorporates a companion diagnostic to identify eligible patients, representing a major step forward in precision medicine for a patient population with limited treatment options.
In September 2025, Labcorp, a U.S.-based provider of comprehensive clinical laboratory services and drug development solutions, purchased select oncology and oncology-related clinical testing assets from BioReference Health for up to $225 million. Through this acquisition, Labcorp seeks to broaden its oncology diagnostics portfolio and enhance nationwide access to high-value cancer testing services by incorporating BioReference’s specialized oncology capabilities and client accounts. BioReference Health is a U.S.-based provider of oncology-focused laboratory testing services, delivering advanced cancer diagnostics, clinical testing solutions, and regional clinical laboratory operations.
Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.
North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pd-l1 and pik3ca testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pd-l1 and pik3ca testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the pd-l1 and pik3ca testing market by increasing costs for imported sequencing kits, reagents, and diagnostic instruments. Hospitals, laboratories, and pharmaceutical companies in Asia-Pacific and Europe are most affected. Segments such as immunohistochemistry and next-generation sequencing kits face higher import costs. Positive impacts include promoting local manufacturing of reagents and kits, fostering innovation, and reducing dependency on international suppliers.
The pd-l1 and pik3ca testing market research report is one of a series of new reports that provides pd-l1 and pik3ca testing market statistics, including pd-l1 and pik3ca testing industry global market size, regional shares, competitors with a pd-l1 and pik3ca testing market share, detailed pd-l1 and pik3ca testing market segments, market trends and opportunities, and any further data you may need to thrive in the pd-l1 and pik3ca testing industry. This pd-l1 and pik3ca testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
PD-L1 and PIK3CA testing are molecular diagnostic methods used to identify specific biomarkers that support targeted cancer treatment decisions. PD-L1 testing measures the expression of the programmed death ligand 1 protein on tumor cells to evaluate the likelihood of response to immunotherapies. PIK3CA testing identifies mutations in the phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha gene, which helps determine eligibility for therapies directed at the PI3K pathway.
The primary test types of PD-L1 and PIK3CA testing include immunohistochemistry, next generation sequencing, polymerase chain reaction, and others. Immunohistochemistry is a laboratory method that applies antibodies to detect specific proteins in tissue samples, making it possible to visualize their location and concentration under a microscope. The sample types used are tissue samples and liquid biopsy samples. The distribution channels include direct sales, distributors and resellers, and online sales platforms. The applications involve cancer diagnosis, drug development, research, and other uses, and they serve multiple end users such as hospitals and clinics, laboratories, and pharmaceutical companies.
The PD-L1 and PIK3CA testing market includes revenues earned by entities through the biomarker testing, molecular diagnostics, genetic mutation detection, generation sequencing services, companion diagnostic testing, pathology interpretation, and clinical trial testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Pd-L1 and Pik3Ca Testing Market Characteristics
3. Pd-L1 and Pik3Ca Testing Market Supply Chain Analysis
4. Global Pd-L1 and Pik3Ca Testing Market Trends and Strategies
5. Pd-L1 and Pik3Ca Testing Market Analysis of End Use Industries
7. Global Pd-L1 and Pik3Ca Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Pd-L1 and Pik3Ca Testing Total Addressable Market (TAM) Analysis for the Market
9. Pd-L1 and Pik3Ca Testing Market Segmentation
10. Pd-L1 and Pik3Ca Testing Market Regional and Country Analysis
11. Asia-Pacific Pd-L1 and Pik3Ca Testing Market
12. China Pd-L1 and Pik3Ca Testing Market
13. India Pd-L1 and Pik3Ca Testing Market
14. Japan Pd-L1 and Pik3Ca Testing Market
15. Australia Pd-L1 and Pik3Ca Testing Market
16. Indonesia Pd-L1 and Pik3Ca Testing Market
17. South Korea Pd-L1 and Pik3Ca Testing Market
18. Taiwan Pd-L1 and Pik3Ca Testing Market
19. South East Asia Pd-L1 and Pik3Ca Testing Market
20. Western Europe Pd-L1 and Pik3Ca Testing Market
21. UK Pd-L1 and Pik3Ca Testing Market
22. Germany Pd-L1 and Pik3Ca Testing Market
23. France Pd-L1 and Pik3Ca Testing Market
24. Italy Pd-L1 and Pik3Ca Testing Market
25. Spain Pd-L1 and Pik3Ca Testing Market
26. Eastern Europe Pd-L1 and Pik3Ca Testing Market
27. Russia Pd-L1 and Pik3Ca Testing Market
28. North America Pd-L1 and Pik3Ca Testing Market
29. USA Pd-L1 and Pik3Ca Testing Market
30. Canada Pd-L1 and Pik3Ca Testing Market
31. South America Pd-L1 and Pik3Ca Testing Market
32. Brazil Pd-L1 and Pik3Ca Testing Market
33. Middle East Pd-L1 and Pik3Ca Testing Market
34. Africa Pd-L1 and Pik3Ca Testing Market
36. Pd-L1 and Pik3Ca Testing Market Competitive Landscape and Company Profiles
37. Pd-L1 and Pik3Ca Testing Market Other Major and Innovative Companies
40. Pd-L1 and Pik3Ca Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
PD-L1 And PIK3CA Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses pd-l1 and pik3ca testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pd-l1 and pik3ca testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pd-l1 and pik3ca testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Immunohistochemistry; Next-Generation Sequencing; Polymerase Chain Reaction2) By Sample Type: Tissue Samples; Liquid Biopsy Samples
3) By Applications: Cancer Diagnosis; Drug Development; Research; Other Applications
4) By End User: Hospitals And Clinics; Laboratories; Pharmaceutical Companies
Subsegments:
1) By Immunohistochemistry: Tissue Staining; Protein Expression Analysis2) By Next-Generation Sequencing: Whole Genome Sequencing; Targeted Gene Sequencing; Exome Sequencing; Ribonucleic Acid (RNA) Sequencing
3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction; Digital Polymerase Chain Reaction
Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Laboratory Corporation of America Holdings (Labcorp); Quest Diagnostics Incorporated; Eurofins Scientific SE; Agilent Technologies Inc.; Sonic Healthcare Limited; Illumina Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Myriad Genetics Inc.; NeoGenomics Laboratories Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Caris Life Sciences; Foundation Medicine Inc.; Amoy Diagnostics Co. Ltd.; ACCB Biotech Private Limited; EntroGen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this PD-L1 and PIK3CA Testing market report include:- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Laboratory Corporation of America Holdings (Labcorp)
- Quest Diagnostics Incorporated
- Eurofins Scientific SE
- Agilent Technologies Inc.
- Sonic Healthcare Limited
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- Myriad Genetics Inc.
- NeoGenomics Laboratories Inc.
- BGI Genomics Co. Ltd.
- Guardant Health Inc.
- Caris Life Sciences
- Foundation Medicine Inc.
- Amoy Diagnostics Co. Ltd.
- ACCB Biotech Private Limited
- EntroGen Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.93 Billion |
| Forecasted Market Value ( USD | $ 3.4 Billion |
| Compound Annual Growth Rate | 15.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
